Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.51 |
| ▸ | CDK1 | P06493 | 17/20 | 0.51 |
| ▸ | CDK2 | P24941 | 17/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774455 | 1.00 | KDR (0.51) | KDRCDK1CDK2MEN1KMT2A | |
| SCHEMBL2148905 | 0.81 | LRRK2 (0.37) | KDRCDK1CDK2 | |
| SCHEMBL2522284 | 0.81 | LRRK2 (0.37) | KDRCDK1CDK2 | |
| SCHEMBL1773659 | 0.80 | KMT2A (0.46) | KDRCDK1CDK2MEN1KMT2A | |
| SCHEMBL3581320 | 0.78 | CDK1 (0.49) | KDRCDK1CDK2MEN1KMT2A | |
| SCHEMBL13648310 | 0.78 | CDK1 (0.49) | KDRCDK1CDK2MEN1KMT2A | |
| SCHEMBL5151881 | 0.78 | CDK1 (0.49) | KDRCDK1CDK2MEN1KMT2A | |
| SCHEMBL23759601 | 0.78 | MEN1 (0.43) | KDRCDK1CDK2MEN1KMT2A | |
| SCHEMBL4592771 | 0.77 | KDR (0.79) | KDRCDK1CDK2 | |
| SCHEMBL4592768 | 0.77 | KDR (0.79) | KDRCDK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735412-B2 | Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8507510-B2 | Sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-20110294838-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | US | disclosed |
| US-7943629-B2 | Anticancer/antitumor agents; S-(4-([4-([(1R,2R)-2-Hydroxy-1-methylpropyl]amino)-5-(trifluoromethyl)-pyrimidin-2-yl]amino)phenyl)-S-methyl-N-[(trifluoromethyl)sulphonyl]-sulphimide for example | BAYER SCHERING PHARMA AG (DE) | 2011-05-17 | — | — | US | disclosed |
| US-20100076000-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-03-25 | — | — | US | disclosed |
| US-7456191-B2 | N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2008-11-25 | — | — | US | disclosed |
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | BAYER SCHERING PHARMA AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-7338958-B2 | Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2008-03-04 | — | — | US | disclosed |
| EP-1861378-A1 | N-ARYL-SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-05 | — | — | EP | disclosed |
| US-20060229325-A1 | N-aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-12 | — | — | US | disclosed |
| WO-2006099974-A1 | N-ARYL-SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-09-28 | — | — | WO | disclosed |
| EP-1705177-A1 | N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-27 | — | — | EP | disclosed |
| US-20060111378-A1 | Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-25 | — | — | US | disclosed |
| US-20050176743-A1 | Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294838-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | CDK6, CDK4, CDK9 | KDR 1083/4885CDK1 6/4885CDK2 4/4885 |
| US-20060111378-A1 | Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents | CDK2, KDR, CDK4 | KDR 2/4885CDK1 5/4885CDK2 1/4885 |
| US-20050176743-A1 | Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | CDK2, CDK1, FLT1 | KDR 12/4885CDK1 2/4885CDK2 1/4885 |
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | PRKCE, BRAF, PACSIN2 | KDR 1439/4885CDK1 160/4885CDK2 49/4885 |
| US-20060229325-A1 | N-aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | CDK2, FLT1, CDK4 | KDR 11/4885CDK1 6/4885CDK2 1/4885 |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | CABLES1, CKS2, CDK2AP1 | KDR 2279/4885CDK1 6/4885CDK2 4/4885 |
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | CDK2, MKI67, ERBB2 | KDR 220/4885CDK1 16/4885CDK2 1/4885 |
| US-20100076000-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | CDK2, CDK1, FLT1 | KDR 12/4885CDK1 2/4885CDK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.